Author： Foster Keith Chaddock John
Publisher： MDPI
E-ISSN： 2072-6651|2|12|2795-2815
ISSN： 2072-6651
Source： Toxins, Vol.2, Iss.12, 2010-12, pp. : 2795-2815
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Botulinum neurotoxins are highly effective therapeutic products. Their therapeutic success results from highly specific and potent inhibition of neurotransmitter release with a duration of action measured in months. These same properties, however, make the botulinum neurotoxins the most potent acute lethal toxins known. Their toxicity and restricted target cell activity severely limits their clinical utility. Understanding the structure-function relationship of the neurotoxins has enabled the development of recombinant proteins selectively incorporating specific aspects of their pharmacology. The resulting proteins are not neurotoxins, but a new class of biopharmaceuticals, Targeted Secretion Inhibitors (TSI), suitable for the treatment of a wide range of diseases where secretion plays a major role. TSI proteins inhibit secretion for a prolonged period following a single application, making them particularly suited to the treatment of chronic diseases. A TSI for the treatment of chronic pain is in clinical development.
Related content
Aptamer-Mediated Targeted Delivery of Therapeutics: An Update
By Catuogno Silvia Esposito Carla L. de Franciscis Vittorio
Pharmaceuticals, Vol. 9, Iss. 4, 2016-11 ,pp. :
Access to resources
Recommend
Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics
Pharmaceuticals, Vol. 10, Iss. 2, 2017-04 ,pp. :
By Lin Jieru E. Valentino Michael Marszalowicz Glen Magee Michael S. Li Peng Snook Adam E. Stoecker Brian A. Chang Chang Waldman Scott A.
Toxins, Vol. 2, Iss. 8, 2010-08 ,pp. :